ANVS - Annovis Bio Inc
2.58
0.010 0.388%
Share volume: 225,166
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.17%
PREVIOUS CLOSE
CHG
CHG%
$2.57
0.01
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-10-2024 | 08-14-2024 | 11-08-2024 | 03-21-2025 | 05-13-2025 | 08-12-2025 | 11-12-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 7.810 M | 7.763 M | 4.388 M | 6.735 M | 6.283 M | 6.271 M | 7.435 M | |
| Selling general and admin | 1.295 M | 1.977 M | 1.698 M | 1.729 M | 1.271 M | 1.110 M | 1.144 M | |
| Research and development | 6.515 M | 5.785 M | 2.690 M | 5.006 M | 5.012 M | 5.162 M | 6.291 M | |
| Total expenses | 7.810 M | 7.763 M | 4.388 M | 6.735 M | 6.283 M | 6.271 M | 7.435 M | |
| -0.60% | -43.48% | 53.50% | -6.71% | -0.18% | 18.55% | |||
| Operating income | -7.810 M | -7.763 M | -4.388 M | -6.735 M | -6.283 M | -6.271 M | -7.435 M | |
| Ebit | -1.111 M | -5.046 M | -12.774 M | -5.991 M | -5.725 M | -6.411 M | -7.415 M | |
| Pretax income | -1.067 M | -5.020 M | -12.638 M | -5.865 M | -5.537 M | -6.220 M | -7.263 M | |
| 370.54% | 151.74% | -53.60% | -5.59% | 12.33% | 16.76% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -1.067 M | -5.020 M | -12.638 M | -5.865 M | -5.537 M | -6.220 M | -7.263 M | |
| -370.54% | -151.74% | 53.60% | 5.59% | -12.33% | -16.76% |